Myelodysplastic Syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Published in 2020 – Ann Oncol (2020)
Authors: P. Fenaux, D. Haase, V. Santini, G.F. Sanz, U. Platzbecker & U. Mey, on behalf of the ESMO Guidelines Committee
Myelodysplastic syndromes (MDS) are clonal haematopoietic stem cell (HSC) disorders predominating in the elderly, with a median age at diagnosis of ~70 years. This ESMO Clinical Practice Guideline provides key recommendations for managing myelodysplastic syndromes. It covers diagnosis, classification, staging and risk assessment of myelodysplastic syndromes. Treatment recommendations for lower- and higher-risk myelodysplastic syndromes are also provided. All recommendations were compiled by a multidisciplinary group of experts. Recommendations are based on available scientific data and the authors’ expert opinion
These Clinical Practice Guidelines are endorsed by the European Hematology Association (EHA).